A meta‐analysis from 28 studies including 3620 patients suggested a lower survival rate of KRAS‐mutated adenocarcinoma (HR = 1.35, 95% CI: 1.16–1.56, P = 0.01), while not in squamous cell carcinoma.28 The gene discussed is KRAS; the disease is adenocarcinoma.